AI Use Cases in Pharma: The Regulated Back Office, Not the Lab
Most writing about AI in pharma is about molecules. Most of the cost, and nearly all of the delay, sits elsewhere: in case processing, in submission assembly, in document control, in the people who read the same batch record so that a lot can ship.
That work is regulated, repetitive, evidence heavy and largely about moving structured facts between systems while proving you did it properly. It is the part of a pharmaceutical company that looks least like science and most like a very careful back office. It is also where agents earn their keep, provided you accept that a regulated environment changes what you have to build, not just what you are allowed to say about it.
Pharmacovigilance: intake and triage at volume
Adverse event intake is the clearest case in the industry. Reports arrive from call centre notes, literature, market research and patient support programmes, partner data exchanges, regulatory inboxes and the channels you are obliged to monitor. Each has to be read, assessed for the minimum criteria, deduplicated, coded, prioritised and entered into the safety database inside a clock that starts the moment anyone in your organisation became aware.
An agent does the first pass. It reads the source document in whatever form it arrived, extracts the reportable elements, proposes coding against your dictionaries, checks the safety database for a probable duplicate with the reasoning shown, drafts the narrative in your house structure, and stages the case for a safety scientist. Everything it proposes carries a pointer back to the exact sentence supporting it, because a case processor's real question is never "what does the agent think", it is "where did that come from".
The same pattern covers literature screening, where the agent applies your inclusion criteria to the search output and presents candidate articles with the relevant passage highlighted rather than a stack of PDFs. It covers the follow up letter when a case is incomplete.
What does not move is seriousness, expectedness, causality and the medical judgement behind them. Those stay with qualified people, and the record should show which person.
Regulatory affairs: dossier assembly and change control
Submission assembly is an enormous exercise in consistency. The same specification, batch analysis and stability conclusion has to appear identically across modules, regional variants and languages, and match the source documents the inspector will eventually ask for.
An agent that has indexed your document management system can assemble a candidate dossier structure, pull the current effective version of each referenced document, and run the cross checks humans currently do by eye: does the shelf life in the summary match the stability report, does the specification in the module match the approved one, is every referenced study present at the version cited, do the regional variants diverge anywhere they should not.
Change control is the other half. When a manufacturing change is proposed, the question that consumes weeks is which registrations, markets, commitments and documents it touches. An agent searches the full controlled set for every reference to the affected site, material, process parameter or method and returns a candidate impact list with citations. Regulatory strategy stays human. The search does not need to be.
Health authority questions follow the same shape: the agent locates the relevant data and prior commitments, and the regulatory lead writes the answer.
Medical information and promotional review
Medical information enquiries are high volume and highly constrained. The answer must come from approved content, must not stray into off label territory, and must be logged. An agent reads the enquiry, classifies it, checks whether it is an adverse event or product complaint in disguise and routes it if so, retrieves the approved standard response document if one exists, and drafts a reply grounded strictly in approved sources with each claim cited. Where no approved content covers the question, it says so rather than composing an answer, and escalates to a medical information specialist.
Promotional material review, the medical, legal and regulatory process, is where marketing timelines die. An agent runs the mechanical layer before the committee meets: every claim matched to its cited reference, references checked for existence and correct version, fair balance and safety information checked against your checklist, prior decisions on similar claims surfaced. Reviewers arrive at a piece with its obvious problems marked and spend the meeting on the arguable ones. Approval remains a committee decision with named signatories.
Manufacturing quality and GxP document control
Batch record review is a completeness and consistency exam. An agent reviews the executed record as soon as it closes, verifies every required entry is present and signed, checks recorded values against the master record limits, re-performs calculations, and cross references any deviation mentioned against the deviation log. Records with findings arrive with each finding located and classified, which is what review by exception was supposed to mean.
Deviation investigation benefits most from evidence assembly. The agent builds the file: process data around the event window, prior deviations on the same line, material and equipment history, applicable procedures, related CAPAs. Investigators start with a curated pack instead of five system logins, and root cause and CAPA decisions stay with them.
Document control is quieter and pays well. An agent monitors the controlled set for procedures past their review date, references to superseded documents, forms that no longer match the procedure calling them, and training assignments never completed after a revision. When an SOP is revised, it drafts the change summary, lists the downstream documents quoting the changed section, and generates the training impact list.
Complaint handling and supplier qualification run on the same machinery: read the complaint or the supplier questionnaire and audit history, classify, check reportability, assemble the file, draft the acknowledgement, and track qualification status against expiry dates.
Clinical operations
Site document management is administrative volume with regulatory teeth. An agent checks incoming trial master file documents against the expected artefact list, verifies signatures and dates are present, confirms the version matches the approved one, and flags missing or expired items per site, so completeness is a live picture rather than a discovery at pre inspection review.
Monitoring visit reports are the other candidate. The monitor notes what happened; the agent drafts the report in the sponsor template, pulls site metrics and open actions from the systems holding them, and flags findings repeating from prior visits. The monitor edits and signs.
Validating a non deterministic system
This is the part that decides whether any of the above survives contact with your quality unit.
Traditional computerised system validation assumes the same input yields the same output, so you specify, test the specified paths, and record that they passed. A language model does not behave that way, and testing one path once proves almost nothing about the next run.
The approach that works treats the agent as a process rather than a calculator. Qualify it statistically against a held out set of real cases with known correct outcomes. Define acceptance criteria as measured performance rather than pass or fail on a script, and monitor that performance in production, not only at release. Treat prompts, retrieval configuration, model versions and tool definitions as controlled, versioned artefacts under change control, because a prompt edit is a system change. A model version change triggers requalification, and your vendor's silent upgrade is a compliance event you need contractual notice of.
Data integrity expectations still apply in full. Every agent action needs an attributable, time stamped, non alterable audit entry showing what it read, what it proposed and what a human did with it. Electronic signature remains human; an agent never signs. The record must let a reviewer reconstruct not just the output but the evidence behind it, which is why source citation is a validation requirement, not a nice touch.
Scope the intended use narrowly and honestly in your validation documentation. An agent drafting for a named human reviewer is a far smaller qualification exercise than one making decisions, and for most of these use cases drafting is all you need.
A brief note on drug discovery
Target identification, molecular property prediction and structure work are a genuinely different discipline: different models, different data, different teams, and results measured in laboratory outcomes rather than cycle time. It is real work and it is not what this article covers. The two rarely share tooling.
Where AI fails here
Patient safety decisions are not delegable. Seriousness, expectedness and causality belong to qualified people, and no measured accuracy figure changes that. The failure mode that should worry you most is a fluent, confident, wrong narrative in a safety report, harder to catch precisely because it reads well. Anything the agent asserts must be traceable to a source a human can check in seconds, and reviewers must stay sceptical rather than becoming rubber stamps, which is the real risk once quality is usually good.
Regulatory accountability sits with named individuals: the qualified person, the qualified person for pharmacovigilance, the signatory on the submission. An agent cannot hold that accountability and should never be positioned as if it does.
The validation burden is real and ongoing, not a one off project, and some use cases will not clear the cost. Organisations that force an agent through a traditional script based validation route either fail the exercise or produce documentation that does not describe the system they run.
Extraction from scanned and handwritten source documents carries genuine error rates, and a confidently misread dose is more dangerous than a flagged unreadable one, so tune for escalation over guessing.
Where to start
Start read only and where ground truth exists. Literature screening, document control monitoring, supplier qualification tracking and reference checking in promotional review are contained, high volume and verifiable against records you already hold. Run the agent in parallel with the human process for a defined period, compare outputs case by case, and use that comparison as both qualification evidence and an honest assessment of whether it is good enough.
Case intake and batch record review are the larger prizes and should follow once the read only foundations are trusted. Have your quality and validation people in the room from day one rather than handing them a finished system.
If you want a plain assessment of which of these an agent could carry in your regulatory context, describe your process to Adopt AI Partners and we will tell you where it holds and where it does not.